SHENZHEN, China, Jan. 26 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) http://www.htdsmedical.com/ the company is pleased to announce that having received clearances from its Chief Project Scientist, Director, R&D, Andrea Zecevic as a viable project for HTDS to merge with Mellow Hope; the company commenced the formulation of an off shore (Belize) special purpose company (SPC). An SPC is required under the Chinese laws before a China mainland company can be merged into a USA based public company such as Hard To Treat Diseases (HTDS).
Cathy Zhao, Chief Admin. Officer for the company said this is a relatively minor task that we need to complete before the actual merger can take place. Our corporate advisors in Canada have done many Asia based SPC and advise us that this should be completed fairly shortly with our targeted early February merger date remaining undisturbed.
In other company news, the company has appointed 2 new officers to the company and the board. They are Li Qiang COO, and Tarun Gupta, Marketing director. Both individuals act in the same capacity with Mellow Hope.
Mellow Hope is China based and the biggest exporter of Biological Vaccines in China. It has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestatin.
Mellow Hope revenues are currently in excess of $15 million USD, and growing.
The company will provide further details as they become available.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
CONTACT: For scientific dialogue and any medical inquiry only please contact Andrea Rubio Zecevic via e-mail at firstname.lastname@example.org. For any corporate matters the readers should contact the company directly at email@example.com
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved